The newly synthesized pyrazole derivative 5-(1-(3 fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole reduces blood pressure of spontaneously hypertensive rats via NO/cGMO pathway

Página do item simplificado
dc.creatorTrindade, Neidiane Rosa
dc.creatorLopes, Paulo Ricardo
dc.creatorNaves, Lara Marques
dc.creatorFajemiroye, James Oluwagbamigbe
dc.creatorAlves, Pedro Henrique
dc.creatorAmaral, Nathalia Oda
dc.creatorLiao, Luciano Morais
dc.creatorRebelo, Ana Cristina Silva
dc.creatorCastro, Carlos Henrique de
dc.creatorBraga, Valdir de Andrade
dc.creatorMenegatti, Ricardo
dc.creatorPedrino, Gustavo Rodrigues
dc.date.accessioned2024-03-05T13:01:23Z
dc.date.available2024-03-05T13:01:23Z
dc.date.issued2018-08
dc.description.abstractThe search for new antihypertensive drugs has grown in recent years because of high rate of morbidity among hypertensive patients and several side effects that are associated with the first-line medications. The current study sought to investigate the antihypertensive effect of a newly synthesized pyrazole derivative known as 5-(1-(3 fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole (LQFM-21). Spontaneously hypertensive rats (SHR) were used to evaluate the effect of LQFM-21 on mean arterial pressure (MAP), heart rate (HR), renal vascular conductance (RVC), arterial vascular conductance (AVC), baroreflex sensitivity (BRS) index, and vascular reactivity. Acute intravenous (iv) administration of LQFM-21 (0.05, 0.1, 0.2, and 0.4 mg kg-1) reduced MAP and HR, and increased RVC and AVC. Chronic oral administration of LQFM-21 (15 mg kg-1) for 15 days reduced MAP without altering BRS. The blockade of muscarinic receptors and nitric oxide synthase by intravenous infusion of atropine and L-NAME, respectively, attenuated cardiovascular effects of LQFM-21. In addition, ex vivo experiments showed that LQFM-21 induced an endothelium-dependent relaxation in isolated aortic rings from SHR. This effect was blocked by guanylyl cyclase inhibitor (ODQ) and L-NAME. These findings suggest the involvement of muscarinic receptor and NO/cGMP pathway in the antihypertensive and vasodilator effects of LQFM-21.
dc.identifier.citationTRINDADE, Neidiane R. et al. The newly synthesized pyrazole derivative 5-(1-(3 fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole reduces blood pressure of spontaneously hypertensive rats via NO/cGMO pathway. Frontiers in Physiology, Lausanne, v. 9, e1073, Aug. 2018. DOI: 10.3389/fphys.2018.01073. Disponível em: https://www.frontiersin.org/articles/10.3389/fphys.2018.01073/full. Acesso em: 16 fev. 2024.
dc.identifier.doi10.3389/fphys.2018.01073
dc.identifier.issne- 1664-042X
dc.identifier.urihttp://repositorio.bc.ufg.br//handle/ri/24473
dc.language.isoeng
dc.publisher.countrySuica
dc.publisher.departmentInstituto de Química - IQ (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSpontaneously hypertensive rats
dc.subjectPyrazole derivative
dc.subjectAntihypertensive drugs
dc.subjectVasodilatation
dc.subjectMuscarinic receptors
dc.titleThe newly synthesized pyrazole derivative 5-(1-(3 fluorophenyl)-1H-pyrazol-4-yl)-2H-tetrazole reduces blood pressure of spontaneously hypertensive rats via NO/cGMO pathway
dc.typeArtigo

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Artigo - Neidiane Rosa Trindade - 2018.pdf
Tamanho:
4.94 MB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IQ - Artigos publicados em periódicos